The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Improving the risk stratification of patients with smoldering myeloma
Romanos Sklavenitis-Pistofidis, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses recent advancements in risk stratification models for smoldering multiple myeloma (SMM) and highlights that the next step to improving prediction of treatment responses and therapy selection should be the routine incorporation of immune profiling in patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
